Partial protection of commercial H5 avian influenza vaccines to clade 2.3.4·4b H5N1 and H5N8 avian influenza infections in chickens

Abstract

Avian influenza viruses (AIVs) continue to cause substantial economic losses to the poultry industry and pose a significant burden on global public health systems. The increasing diversity and geographical spread of different subtypes of influenza viruses in poultry populations increases the risk for reassortment events and the emergence of novel strains. Vaccination remains a key strategy for preventing influenza infection and its complications, especially high pathogenic avian influenza (HPAI), as it can reduce morbidity, mortality, and viral transmission. However, vaccine effectiveness is closely tied to the antigenic match between vaccine strains and circulating viruses. In this study, we tested six commonly used commercial poultry H5 vaccines in Egypt to evaluate mortality, and virus shedding following experimental infection of specific pathogen free chickens with clade 2.3.4·4b H5N1 and H5N8 HPAI viruses. Our results showed that most of the tested vaccines provided detectable antibody titers and protected against mortality but were not able to control virus shedding. ValleyVac vaccines induced high HI titers (up to 9 log2) against recent clade 2.3.4·4b A(H5N1) and A(H5N8) strains, while Zoetis and Egy-flu R 2-in-1 induced lower HI titers (<6 log2). Although some of the commercial vaccines did not elicit considerable HI titers, vaccines provided 71%–100% protection against clade 2.3.4·4b viruses. Importantly, virus titers were detected till seven days post-infection (dpi). This incomplete protection is likely due to genetic and antigenic mismatches between the vaccine seed strains and the H5N1 and H5N8 viruses detected in Egypt. These results highlight the urgent need to revise H5Nx prevention and control strategies in Egypt and update vaccine seed strains to reflect currently circulating HPAI viruses.